Jacob Gottlieb Altium

Jacob Gottlieb, a healthcare investment mogul who founded Visium Asset Management, has started a new healthcare investment firm, Altium Capital. Gottlieb looks to build upon his previous success in healthcare investment.

Jacob Gottlieb earned a Bachelor of Arts in economics from Brown University and graduated magna cum laude. Later, he completed his medical doctorate degree from NYU Medical School. After completing medical school, Gottlieb participated in a medical internship at St. Vincent’s Hospital. It was during this internship when he shifted his career path toward finance.

Gottlieb began his investment career as an analyst at Sanford C. Bernstein & Co. During this same time, he achieved Certified Financial Analyst (CFA) designation. Gottlieb then left Sanford to begin his career as a healthcare portfolio manager for Merlin Biomed Group. After moving to Balyasny Asset Management, he became a top earner. These experiences eventually led him to start Visium Asset Management in 2005.

Visium attracted talented advisers who helped raise over $300 million in capital. Its portfolio managers saw significant success, with an $8 billion dollar fund. Visium maintained offices in New York and San Francisco, with an officer overseas in London, and employed over 170 employees.

Unfortunately, Visium’s success ended when three of its employees were charged with securities mismanagement and insider trading by the SEC and U.S. Attorney’s Office. As a result of these issues, Gottlieb decided to close Visium in 2016.

Jacob Gottlieb has given his new investment venture, Altium Capital, his full attention. As a result of his previous investment success, he has a large network in the profession. This has allowed Altium to open offices in New York City, where it shares offices with Bay City Capital and Iguana Healthcare Partners.

With Altium, Gottlieb has initially invested in Sellas Life Sciences and Oramed Pharmaceuticals Inc., which are both pharmaceutical companies with innovative products awaiting FDA approval. These products could have a significant effect on the market and are viewed as strategic investment moves by Gottlieb to advance his new venture.

Find out more about Jacob Gottlieb: https://www.linkedin.com/in/jacob-gottlieb/